Combating the epigenome: Epigenetic drugs against non-Hodgkin's lymphoma

Epigenomics

Volumn 5, Issue 4, 2013, Pages 397-415

  Hassler, Melanie R ^a   Schiefer, Ana Iris ^a   Egger, Gerda ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

bromodomain inhibitor; chromatin remodeling; DNA methyltransferase inhibitor; epigenetic therapy; histone deacetylase inhibitor; histone methyltransferase inhibitor; non Hodgkin's lymphoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ABEXINOSTAT; ADENOSINE DIALDEHYDE; AZACITIDINE; BELINOSTAT; CYTIDINE DEAMINASE; DNA METHYLTRANSFERASE; ENTINOSTAT; GIVINOSTAT; MOCETINOSTAT; N (1 BENZYL 4 PIPERIDINYL) 2 (HEXAHYDRO 4 METHYL 1H 1,4 DIAZEPIN 1 YL) 6,7 DIMETHOXY 4 QUINAZOLINAMINE; PANOBINOSTAT; QUISINOSTAT; ROMIDEPSIN; SINEFUNGIN; TETRAHYDROURIDINE; TRICHOSTATIN A; VORINOSTAT; ZEBULARINE;

ANEMIA; ANOREXIA; B CELL LYMPHOMA; B LYMPHOCYTE; BONE MARROW SUPPRESSION; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER FATIGUE; CELL DIFFERENTIATION; CHROMATIN; CLINICAL FEATURE; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DNA METHYLATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG TOLERABILITY; DRUG UPTAKE; EPIGENETICS; FATIGUE; FOLLICULAR LYMPHOMA; GENE MUTATION; HAIRY CELL LEUKEMIA; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LYMPHOCYTE DIFFERENTIATION; LYMPHOMATOID GRANULOMATOSIS; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MYCOSIS FUNGOIDES; NATURAL KILLER CELL; NAUSEA; NK T CELL LYMPHOMA; NODAL MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PLASMABLASTIC LYMPHOMA; PLASMACYTOMA; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; PROMYELOCYTIC LEUKEMIA; REVIEW; T CELL LEUKEMIA; T LYMPHOCYTE; VOMITING; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA METHYLATION; DRUG DELIVERY SYSTEMS; EPIGENESIS, GENETIC; EPIGENOMICS; HISTONE DEACETYLASE INHIBITORS; HUMANS; LYMPHOMA, NON-HODGKIN; STEM CELL TRANSPLANTATION;

EID: 84881090160     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.13.39     Document Type: Review

References (201)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107(1), 265-276 (2006
2. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84(5), 1361-1392 (1994
3. Swerdlow S, Campo E, Harris N, Al E. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition). International Agency for Research on Cancer Press, Lyon, France, 214-217 (2008
4. Martin-Subero JI, Lopez-Otin C, Campo E. Genetic and epigenetic basis of chronic lymphocytic leukemia. Curr. Opin. Hematol. 20(4), 362-368 (2013
5. Piccaluga PP, Agostinelli C, Califano A et al. Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res. 67(22), 10703-10710 (2007
6. Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T cell lymphoma. Leukemia 20(2), 313-318 (2006
7. Kohno T, Yamada Y, Akamatsu N et al. Possible origin of adult T cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells. Cancer Sci. 96(8), 527-533 (2005
8. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-Associated non-Hodgkin lymphoma. Lancet 337(8745), 805-809 (1991
9. Canioni D, Jabado N, Macintyre E, Patey N, Emile JF, Brousse N. Lymphoproliferative disorders in children with primary immunodeficiencies: Immunological status may be more predictive of the outcome than other criteria. Histopathology 38(2), 146-159 (2001
10. Kassan SS, Thomas TL, Moutsopoulos HM et al. Increased risk of lymphoma in sicca syndrome. Ann. Intern. Med. 89(6), 888-892 (1978
11. Hamilton-Dutoit SJ, Rea D, Raphael M et al. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am. J. Pathol. 143(4), 1072-1085 (1993
12. Du MQ, Bacon CM, Isaacson PG. Kaposi sarcoma-Associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J. Clin. Pathol. 60(12), 1350-1357 (2007
13. Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc. Natl Acad. Sci. USA 103(3), 720-725 (2006
14. Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: Epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 117(6), 1792-1798 (2011
15. Guidoboni M, Ferreri AJ, Ponzoni M, Doglioni C, Dolcetti R. Infectious agents in mucosa-Associated lymphoid tissue-Type lymphomas: Pathogenic role and therapeutic perspectives. Clin. Lymphoma Myeloma 6(4), 289-300 (2006
16. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 31(11), 1860-1861 (1971
17. Project TIN-HSLPF. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N .Engl. J. Med. 329(14), 987-994 (1993
18. Siebert R, Rosenwald A, Staudt LM, Morris SW. Molecular features of B cell lymphoma. Curr. Opin. Oncol. 13(5), 316-324 (2001
19. Jares P, Campo E, Pinyol M et al. Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am. J. Pathol. 148(5), 1591-1600 (1996
20. Quintanilla-Martinez L, Davies-Hill T, Fend F et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): Implications for pathogenesis. Blood 101(8), 3181-3187 (2003
21. Carvajal-Cuenca A, Sua LF, Silva NM et al. In situ mantle cell lymphoma: Clinical implications of an incidental finding with indolent clinical behavior. Haematologica 97(2), 270-278 (2012
22. Jegalian AG, Eberle FC, Pack SD et al. Follicular lymphoma in situ: Clinical implications and comparisons with partial involvement by follicular lymphoma. Blood 118(11), 2976-2984 (2011
23. Zhang Q, Siebert R, Yan M et al. Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14) (p22;q32). Nat. Genet. 22(1), 63-68 (1999
24. Zech L, Haglund U, Nilsson K, Klein G. Characteristic chromosomal abnormalities in biopsies and lymphoid cell lines from patients with Burkitt and non-Burkitt lymphomas. Int. J. Cancer 17(1), 47-56 (1976
25. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 403(6769), 503-511 (2000
26. Huang Y, De Reyniès A, De Leval L et al. Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T cell lymphoma, nasal type. Blood 115(6), 1226-1237 (2010
27. Piccaluga PP, Agostinelli C, Califano A et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J. Clin. Invest. 117(3), 823-834 (2007
28. Bellan C, Lazzi S, De Falco G, Nyongo A, Giordano A, Leoncini L. Burkitt's lymphoma: New insights into molecular pathogenesis. J. Clin. Pathol. 56(3), 188-192 (2003
29. Hagelkruys A, Sawicka A, Rennmayr M, Seiser C. The biology of HDAC in cancer: The nuclear and epigenetic components. Handb. Exp. Pharmacol. 206, 13-37 (2011
30. Marquard L, Poulsen CB, Gjerdrum LM et al Histone deacetylase 1, 2, 6 and acetylated histone H4 in B-And T cell lymphomas. Histopathology 54(6), 688-698 (2009
31. Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T cell lymphoma. Histopathology 53(3), 267-277 (2008
32. Minucci S, Pelicci PG. Retinoid receptors in health and disease: Co-regulators and the chromatin connection. Semin. Cell Dev. Biol. 10(2), 215-225 (1999
33. Pasqualucci L, Bereschenko O, Niu H et al. Molecular pathogenesis of non-Hodgkin's lymphoma: The role of Bcl-6. Leuk. Lymphoma 44(Suppl. 3), S5-S12 (2003
34. Zhang X, Chen X, Lin J et al. Myc represses miR-15a/miR-16-11 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B cell lymphomas. Oncogene 31(24), 3002-3008 (2012
35. Zhang X, Zhao X, Fiskus W et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B cell lymphomas. Cancer Cell 22(4), 506-523 (2012
36. Gupta M, Han JJ, Stenson M, Wellik L, Witzig TE. Regulation of STAT3 by histone deacetylase 3 in diffuse large B cell lymphoma: Implications for therapy. Leukemia 26(6), 1356-1364 (2012
37. Bracken AP, Helin K. Polycomb group proteins: Navigators of lineage pathways led astray in cancer. Nat. Rev. Cancer 9(11), 773-784 (2009
38. Velichutina I, Shaknovich R, Geng H et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 116(24), 5247-5255 (2010
39. van Galen JC, Dukers DF, Giroth C et al. Distinct expression patterns of polycomb oncoproteins and their binding partners during the germinal center reaction. Eur. J. Immunol. 34(7), 1870-1881 (2004
40. Morin RD, Johnson NA, Severson TM et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B cell lymphomas of germinal-center origin. Nat. Genet. 42(2), 181-185 (2010
41. Love C, Sun Z, Jima D et al. The genetic landscape of mutations in Burkitt lymphoma. Nat. Genet. 44(12), 1321-1325 (2012
42. Nikoloski G, Langemeijer SM, Kuiper RP et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat. Genet. 42(8), 665-667 (2010
43. Visser HP, Gunster MJ, Kluin-Nelemans HC et al. The polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br. J. Haematol. 112(4), 950-958 (2001
44. Eckerle S, Brune V, Döring C et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: Insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 23(11), 2129-2138 (2009
45. Sasaki D, Imaizumi Y, Hasegawa H et al. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica 96(5), 712-719 (2011
46. Majer CR, Jin L, Scott MP et al. A687V EZH2 is a gain-of-function mutation found in lymphoma patients. FEBS Lett. 586(19), 3448-3451 (2012
47. McCabe MT, Graves AP, Ganji G et al. Mutation of A677 in histone methyltransferase EZH2 in human B cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl Acad. Sci. USA 109(8), 2989-2994 (2012
48. Yap DB, Chu J, Berg T et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117(8), 2451-2459 (2011
49. Agger K, Cloos PA, Christensen J et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449(7163), 731-734 (2007
50. Lan F, Bayliss PE, Rinn JL et al. A histone H3 lysine 27 demethylase regulates animal posterior development. Nature 449(7163), 689-694 (2007
51. Lee MG, Villa R, Trojer P et al. Demethylation of H3K27 regulates polycomb recruitment and H2A ubiquitination. Science 318(5849), 447-450 (2007
52. McCabe MT, Ott HM, Ganji G et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-Activating mutations. Nature 492(7427), 108-112 (2012
53. van Haaften G, Dalgliesh GL, Davies H et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat. Genet. 41(5), 521-523 (2009
54. Morin RD, Mendez-Lago M, Mungall AJ et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476(7360), 298-303 (2011
55. Pasqualucci L, Trifonov V, Fabbri G et al. Analysis of the coding genome of diffuse large B cell lymphoma. Nat. Genet. 43(9), 830-837 (2011
56. Lohr JG, Stojanov P, Lawrence MS et al. Discovery and prioritization of somatic mutations in diffuse large B cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl Acad. Sci. USA 109(10), 3879-3884 (2012
57. Shilatifard A. Chromatin modifications by methylation and ubiquitination: Implications in the regulation of gene expression. Annu. Rev. Biochem. 75, 243-269 (2006
58. Issaeva I, Zonis Y, Rozovskaia T et al. Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth. Mol. Cell. Biol. 27(5), 1889-1903 (2007
59. Yuan ZL, Guan YJ, Chatterjee D, Chin YE. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 307(5707), 269-273 (2005
60. Pasqualucci L, Dominguez-Sola D, Chiarenza A et al. Inactivating mutations of acetyltransferase genes in B cell lymphoma. Nature 471(7337), 189-195 (2011
61. Pasini D, Malatesta M, Jung HR et al. Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of polycomb group target genes. Nucleic Acids Res. 38(15), 4958-4969 (2010
62. Martín-Pérez D, Sánchez E, Maestre L et al. Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma. Am. J. Pathol. 177(2), 930-942 (2010
63. van Kemenade FJ, Raaphorst FM, Blokzijl T et al. Coexpression of BMI 1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B cell non-Hodgkin lymphoma. Blood 97(12), 3896-3901 (2001
64. Martín-Subero JI, Kreuz M, Bibikova M et al. New insights into the biology and origin of mature aggressive B cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 113(11), 2488-2497 (2009
65. Widschwendter M, Fiegl H, Egle D et al. Epigenetic stem cell signature in cancer. Nat. Genet. 39(2), 157-158 (2007
66. Gal-Yam EN, Egger G, Iniguez L et al. Frequent switching of polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc. Natl Acad. Sci. USA 105(35), 12979-12984 (2008
67. Ehrich M, Turner J, Gibbs P et al. Cytosine methylation profiling of cancer cell lines. Proc. Natl Acad. Sci. USA 105(12), 4844-4849 (2008
68. Challen GA, Sun D, Jeong M et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet. 44(1), 23-31 (2011
69. Couronné L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T cell lymphoma. N .Engl. J. Med. 366(1), 95-96 (2012
70. Shah MY, Vasanthakumar A, Barnes NY et al. DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer Res. 70(14), 5840-5850 (2010
71. Vasanthakumar A, Lepore JB, Zegarek MH et al. Dnmt3b is a haploinsufficient tumor suppressor gene in Myc-induced lymphomagenesis. Blood 121(11), 2059-2063 (2013
72. Amara K, Ziadi S, Hachana M, Soltani N, Korbi S, Trimeche M. DNA methyltransferase DNMT3b protein overexpression as a prognostic factor in patients with diffuse large B cell lymphomas. Cancer Sci. 101(7), 1722-1730 (2010
73. Bröske AM, Vockentanz L, Kharazi S et al. DNA methylation protects hematopoietic stem cell multipotency from myeloerythroid restriction. Nat. Genet. 41(11), 1207-1215 (2009
74. Trowbridge JJ, Snow JW, Kim J, Orkin SH. DNA methyltransferase 1 is essential for and uniquely regulates hematopoietic stem and progenitor cells. Cell Stem Cell 5(4), 442-449 (2009
75. Trowbridge JJ, Sinha AU, Zhu N, Li M, Armstrong SA, Orkin SH. Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev. 26(4), 344-349 (2012
76. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990), 457-463 (2004
77. Cheng JC, Matsen CB, Gonzales FA et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl Cancer Inst. 95(5), 399-409 (2003
78. Santi DV, Garrett CE, Barr PJ. On the mechanism of inhibition of DNA-cytosine methyltransferases by cytosine analogs. Cell 33(1), 9-10 (1983
79. Santi DV, Norment A, Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-Azacytosine. Proc. Natl Acad. Sci. USA 81(22), 6993-6997 (1984
80. Kantarjian HM, Issa JP. Decitabine dosing schedules. Semin. Hematol. 42(3 Suppl. 2), S17-S22 (2005
81. Lee TT, Karon MR. Inhibition of protein synthesis in 5-Azacytidine- Treated HeLa cells. Biochem. Pharmacol. 25(15), 1737-1742 (1976
82. Ogama Y, Ouchida M, Yoshino T et al. Prevalent hyper-methylation of the CDH13 gene promoter in malignant B cell lymphomas. Int. J. Oncol. 25(3), 685-691 (2004
83. Agrelo R, Setien F, Espada J et al. Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B cell lymphoma. J. Clin. Oncol. 23(17), 3940-3947 (2005
84. Hassler MR, Klisaroska A, Kollmann K et al. Antineoplastic activity of the DNA methyltransferase inhibitor 5-Aza-2́-deoxycytidine in anaplastic large cell lymphoma. Biochimie 94(11), 2297-2307 (2012
85. Han Y, Amin HM, Frantz C et al. Restoration of shp1 expression by 5-AZA-2́-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma. Leukemia 20(9), 1602-1609 (2006
86. Qin T, Jelinek J, Si J, Shu J, Issa JP. Mechanisms of resistance to 5-Aza-2́-deoxycytidine in human cancer cell lines. Blood 113(3), 659-667 (2009
87. Momparler RL. Pharmacology of 5-Aza-2́-deoxycytidine (decitabine). Semin. Hematol. 42(3 Suppl. 2), S9-S16 (2005
88. Samlowski WE, Leachman SA, Wade M et al. Evaluation of a 7 day continuous intravenous infusion of decitabine: Inhibition of promoter-specific and global genomic DNA methylation. J. Clin. Oncol. 23(17), 3897-3905 (2005
89. Karahoca M, Momparler RL. Pharmacokinetic and pharmacodynamic analysis of 5-Aza-2́-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin. Epigenetics 5(1), 3 (2013
90. Lavelle D, Vaitkus K, Ling Y et al. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood 119(5), 1240-1247 (2012
91. Momparler RL, Goodman J. In vitro cytotoxic and biochemical effects of 5-Aza-2́-deoxycytidine. Cancer Res. 37(6), 1636-1639 (1977
92. Issa JP, Garcia-Manero G, Giles FJ et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-Aza-2́- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103(5), 1635-1640 (2004
93. Kaminskas E, Farrell A, Abraham S et al. Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes. Clin. Cancer Res. 11(10), 3604-3608 (2005
94. Blum KA, Liu Z, Lucas DM et al. Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: Dose-limiting myelosuppression without evidence of DNA hypomethylation. Br. J. Haematol. 150(2), 189-195 (2010
95. Stewart DJ, Issa JP, Kurzrock R et al. Decitabine effect on tumor global DNA methylation and other parameters in a Phase I trial in refractory solid tumors and lymphomas. Clin. Cancer Res. 15(11), 3881-3888 (2009
96. Stathis A, Hotte SJ, Chen EX et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin. Cancer Res. 17(6), 1582-1590 (2011
97. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21(1), 103-107 (1999
98. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6(1), 38-51 (2006
99. Bradner JE, West N, Grachan ML et al. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6(3), 238-243 (2010
100. Hu E, Dul E, Sung CM et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307(2), 720-728 (2003
101. Vannini A, Volpari C, Filocamo G et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl Acad. Sci. USA 101(42), 15064-15069 (2004
102. Inoue S, Mai A, Dyer MJ, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 66(13), 6785-6792 (2006
103. Santo L, Hideshima T, Kung AL et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 119(11), 2579-2589 (2012
104. Fournel M, Bonfils C, Hou Y et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol. Cancer Ther. 7(4), 759-768 (2008
105. Lin RJ, Egan DA, Evans RM. Molecular genetics of acute promyelocytic leukemia. Trends Genet. 15(5), 179-184 (1999
106. He LZ, Tolentino T, Grayson P et al. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J. Clin. Invest. 108(9), 1321-1330 (2001
107. Kalac M, Scotto L, Marchi E et al. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL. Blood 118(20), 5506-5516 (2011
108. Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T cell lymphoma cells: Relevance to mechanism of therapeutic action. J. Invest. Dermatol. 125(5), 1045-1052 (2005
109. Piekarz RL, Robey RW, Zhan Z et al. T cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: Impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 103(12), 4636-4643 (2004
110. Camphausen K, Burgan W, Cerra M et al Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res. 64(1), 316-321 (2004
111. Munshi A, Kurland JF, Nishikawa T et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 11(13), 4912-4922 (2005
112. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-Associated histone acetylation. Proc. Natl Acad. Sci. USA 97(18), 10014-10019 (2000
113. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc. Natl Acad. Sci. USA 101(52), 18030-18035 (2004
114. Insinga A, Monestiroli S, Ronzoni S et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med. 11(1), 71-76 (2005
115. Nebbioso A, Clarke N, Voltz E et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 11(1), 77-84 (2005
116. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell 133(4), 612-626 (2008
117. Guan JS, Haggarty SJ, Giacometti E et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459(7243), 55-60 (2009
118. Heideman MR, Wilting RH, Yanover E et al. Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood 121(11), 2038-2050 (2013
119. Santoro F, Botrugno OA, Dal Zuffo R et al. A dual role for HDAC1: Oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 121(17), 3459-3468 (2013
120. Dovey OM, Foster CT, Conte N et al. Histone deacetylase 1 and 2 are essential for normal T cell development and genomic stability in mice. Blood 121(8), 1335-1344 (2013
121. Gloghini A, Buglio D, Khaskhely NM et al. Expression of histone deacetylases in lymphoma: Implication for the development of selective inhibitors. Br. J. Haematol. 147(4), 515-525 (2009
122. Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T cell lymphomas. Leukemia 22(5), 1026-1034 (2008
123. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T cell lymphoma. Oncologist 12(10), 1247-1252 (2007
124. Younes A, Wedgwood A, McLaughlin P et al. Treatment of relapsed or refractory lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a Phase II study. Blood 110(11), Abstract 2571 (2007
125. Gore L, Rothenberg ML, O'Bryant CL et al. A Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin. Cancer Res. 14(14), 4517-4525 (2008
126. Piekarz RL, Frye R, Turner M et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T cell lymphoma. J. Clin. Oncol. 27(32), 5410-5417 (2009
127. Ryan QC, Headlee D, Acharya M et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 23(17), 3912-3922 (2005
128. Kelly WK, O'Connor OA, Krug LM et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23(17), 3923-3931 (2005
129. Sandor V, Bakke S, Robey RW et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8(3), 718-728 (2002
130. Garcia-Manero G, Assouline S, Cortes J et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood 112(4), 981-989 (2008
131. Zain J. Role of histone deacetylase inhibitors in the treatment of lymphomas and multiple myeloma. Hematol. Oncol. Clin. North Am. 26(3), 671-704, ix (2012
132. Bertino EM, Otterson GA. Romidepsin: A novel histone deacetylase inhibitor for cancer. Expert Opin. Investig. Drugs 20(8), 1151-1158 (2011
133. Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T cell lymphoma. J. Clin. Oncol. 25(21), 3109-3115 (2007
134. Duvic M, Talpur R, Ni X et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T cell lymphoma (CTCL). Blood 109(1), 31-39 (2007
135. Kirschbaum M, Frankel P, Popplewell L et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncol. 29(9), 1198-1203 (2011
136. Crump M, Coiffier B, Jacobsen ED et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B cell lymphoma. Ann. Oncol. 19(5), 964-969 (2008
137. Whittaker SJ, Demierre MF, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T cell lymphoma. J. Clin. Oncol. 28(29), 4485-4491 (2010
138. Coiffier B, Pro B, Prince HM et al. Results from a pivotal, open-label, Phase II study of romidepsin in relapsed or refractory peripheral T cell lymphoma after prior systemic therapy. J. Clin. Oncol. 30(6), 631-636 (2012
139. Piekarz RL, Frye R, Prince HM et al. Phase 2 trial of romidepsin in patients with peripheral T cell lymphoma. Blood 117(22), 5827-5834 (2011
140. Duvic M, Becker J, Dalle S et al. Phase II trial of oral panobinostat (LBH589) in patients with refractory cutaneous T cell lymphoma (CTCL). Blood 112(11), Abstract 1005 (2008
141. Tan J, Yang X, Zhuang L et al. Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21(9), 1050-1063 (2007
142. Miranda TB, Cortez CC, Yoo CB et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8(6), 1579-1588 (2009
143. Fiskus W, Rao R, Balusu R et al. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells. Clin. Cancer Res. 18(22), 6227-6238 (2012
144. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat. Chem. Biol. 1(3), 143-145 (2005
145. Zheng W, Ibáñez G, Wu H et al. Sinefungin derivatives as inhibitors and structure probes of protein lysine methyltransferase SETD2. J. Am. Chem. Soc. 134(43), 18004-18014 (2012
146. Williams DE, Dalisay DS, Li F et al. Nahuoic acid A produced by a Streptomyces sp. isolated from a marine sediment is a selective SAM-competitive inhibitor of the histone methyltransferase SETD8. Org. Lett. 15(2), 414-417 (2013
147. Kubicek S, O'sullivan RJ, August EM et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell. 25(3), 473-481 (2007
148. Knutson SK, Wigle TJ, Warholic NM et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8(11), 890-896 (2012
149. Filippakopoulos P, Knapp S. The bromodomain interaction module. FEBS Lett. 586(17), 2692-2704 (2012
150. Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. Structure and ligand of a histone acetyltransferase bromodomain. Nature 399(6735), 491-496 (1999
151. Mujtaba S, He Y, Zeng L et al. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol. Cell. 13(2), 251-263 (2004
152. Fitzgerald KT, Diaz MO. MLL2: A new mammalian member of the trx/MLL family of genes. Genomics 59(2), 187-192 (1999
153. Shen W, Xu C, Huang W et al. Solution structure of human Brg1 bromodomain and its specific binding to acetylated histone tails. Biochemistry 46(8), 2100-2110 (2007
154. Filippakopoulos P, Qi J, Picaud S et al. Selective inhibition of BET bromodomains. Nature 468(7327), 1067-1073 (2010
155. Nicodeme E, Jeffrey KL, Schaefer U et al. Suppression of inflammation by a synthetic histone mimic. Nature 468(7327), 1119-1123 (2010
156. Chung CW, Coste H, White JH et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J. Med. Chem. 54(11), 3827-3838 (2011
157. Delmore JE, Issa GC, Lemieux ME et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6), 904-917 (2011
158. Mertz JA, Conery AR, Bryant BM et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl Acad. Sci. USA 108(40), 16669-16674 (2011
159. Momparler RL. Cancer epigenetics. Oncogene 22(42), 6479-6483 (2003
160. Hiraga J, Tomita A, Sugimoto T et al. Down-regulation of CD20 expression in B cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: Its prevalence and clinical significance. Blood 113(20), 4885-4893 (2009
161. Shi W, Han X, Yao J, Yang J, Shi Y. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis. Leukemia Res. 36(6), 749-755 (2012
162. Ageberg M, Rydstrom K, Relander T, Drott K. The histone deacetylase inhibitor valproic acid sensitizes diffuse large B cell lymphoma cell lines to CHOP-induced cell death. Am. J. Transl. Res. 5(2), 170-183 (2013
163. Dos Santos Ferreira AC, Fernandes RA, Kwee JK, Klumb CE. Histone deacetylase inhibitor potentiates chemotherapy-induced apoptosis through Bim upregulation in Burkitt's lymphoma cells. J. Cancer Res. Clin. Oncol. 138(2), 317-325 (2012
164. Nagarajan RP, Fouse SD, Bell RJ, Costello JF. Methods for cancer epigenome analysis. Adv. Exp. Med. Biol. 754, 313-338 (2013
165. Clark SS, Mclaughlin J, Timmons M et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science 239(4841 Pt 1), 775-777 (1988
166. Carroll AJ, Crist WM, Parmley RT, Roper M, Cooper MD, Finley WH Pre B cell leukemia associated with chromosome translocation 1;19. Blood 63(3), 721-724 (1984
167. Lillington DM, Young BD, Berger R, Martineau M, Moorman AV, Secker-Walker LM. The t(10;11)(p12;q23) translocation in acute leukaemia: A cytogenetic and clinical study of 20 patients. European 11q23 Workshop participants. Leukemia 12(5), 801-804 (1998
168. Romana SP, Le Coniat M, Berger R. t(12;21): A new recurrent translocation in acute lymphoblastic leukemia. Genes Chromosomes Cancer 9(3), 186-191 (1994
169. Gesk S, Klapper W, Martin-Subero JI et al. A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood 108(3), 1109-1110 (2006
170. Horsman DE, Okamoto I, Ludkovski O et al. Follicular lymphoma lacking the t(14;18) (q32;q21): Identification of two disease subtypes. Br. J. Haematol. 120(3), 424-433 (2003
171. Aarts WM, Willemze R, Bende RJ, Meijer CJ, Pals ST, Van Noesel CJ. VH gene analysis of primary cutaneous B cell lymphomas: Evidence for ongoing somatic hypermutation and isotype switching. Blood 92(10), 3857-3864 (1998
172. Dohner H, Stilgenbauer S, Dohner K, Bentz M, Lichter P. Chromosome aberrations in B cell chronic lymphocytic leukemia: Reassessment based on molecular cytogenetic analysis. J. Mol. Med. (Berl.) 77(2), 266-281 (1999
173. Stilgenbauer S, Lichter P, Dohner H. Genetic features of B cell chronic lymphocytic leukemia. Rev. Clin. Exp. Hematol. 4(1), 48-72 (2000
174. Akagi T, Motegi M, Tamura A et al. A novel gene, MALT1 at 18q21, is involved in t(11;18) (q21;q21) found in low-grade B cell lymphoma of mucosa-Associated lymphoid tissue. Oncogene 18(42), 5785-5794 (1999
175. Streubel B, Lamprecht A, Dierlamm J et al. T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood
176. Streubel B, Vinatzer U, Lamprecht A, Raderer M, Chott A. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia 19(4), 652-658 (2005
177. Martin-Subero JI, Ibbotson R, Klapper W et al. A comprehensive genetic and histopathologic analysis identifies two subgroups of B cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-Translocation. Leukemia 21(7), 1532-1544 (2007
178. Gazzo S, Baseggio L, Coignet L et al. Cytogenetic and molecular delineation of a region of chromosome 3q commonly gained in marginal zone B cell lymphoma. Haematologica 88(1), 31-38 (2003
179. Sambani C, Trafalis DT, Mitsoulis-Mentzikoff C et al. Clonal chromosome rearrangements in hairy cell leukemia: Personal experience and review of literature. Cancer Genet. Cytogenet. 129(2), 138-144 (2001
180. Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B cell malignancies. Blood 96(3), 808-822 (2000
181. Schop RF, Kuehl WM, Van Wier SA et al. Waldenstrom macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 100(8), 2996-3001 (2002
182. Poulain S, Roumier C, Decambron A et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 121(22), 4504-4511 (2013
183. Ngo VN, Young RM, Schmitz R et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 470(7332), 115-119 (2011
184. Franke S, Wlodarska I, Maes B et al. Comparative genomic hybridization pattern distinguishes T cell/histiocyte-rich B cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma. Am. J. Pathol. 161(5), 1861-1867 (2002
185. Hallermann C, Kaune KM, Gesk S et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B cell lymphomas. J. Invest. Dermatol. 123(1), 213-219 (2004
186. Wessendorf S, Barth TF, Viardot A et al. Further delineation of chromosomal consensus regions in primary mediastinal B cell lymphomas: An analysis of 37 tumor samples using high-resolution genomic profiling (array-CGH). Leukemia 21(12), 2463-2469 (2007
187. Gesk S, Gascoyne RD, Schnitzer B et al. ALK-positive diffuse large B cell lymphoma with ALK-Clathrin fusion belongs to the spectrum of pediatric lymphomas. Leukemia 19(10), 1839-1840 (2005
188. Schmitz R, Young RM, Ceribelli M et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490(7418), 116-120 (2012
189. Graux C, Cools J, Michaux L, Vandenberghe P, Hagemeijer A. Cytogenetics and molecular genetics of T cell acute lymphoblastic leukemia: From thymocyte to lymphoblast. Leukemia 20(9), 1496-1510 (2006
190. Virgilio L, Narducci MG, Isobe M et al. Identification of the TCL1 gene involved in T cell malignancies. Proc. Natl Acad. Sci. USA 91(26), 12530-12534 (1994
191. Stern MH, Soulier J, Rosenzwajg M et al. MTCP-1: A novel gene on the human chromosome Xq28 translocated to the T cell receptor alpha/delta locus in mature T cell proliferations. Oncogene 8(9), 2475-2483 (1993
192. Nakashima Y, Tagawa H, Suzuki R et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: Different genomic alteration patterns of aggressive NK cell leukemia and extranodal Nk/T cell lymphoma, nasal type. Genes Chromosomes Cancer 44(3), 247-255 (2005
193. Przybylski GK, Dik WA, Wanzeck J et al. Disruption of the BCL11B gene through inv(14)(q11.2q32.31) results in the expression of BCL11B-TRDC fusion transcripts and is associated with the absence of wild-Type BCL11B transcripts in T ALL. Leukemia 19(2), 201-208 (2005
194. Oshiro A, Tagawa H, Ohshima K et al. Identification of subtype-specific genomic alterations in aggressive adult T cell leukemia/lymphoma. Blood 107(11), 4500-4507 (2006
195. Siu LL, Chan V, Chan JK, Wong KF, Liang R, Kwong YL. Consistent patterns of allelic loss in natural killer cell lymphoma. Am. J. Pathol. 157(6), 1803-1809 (2000
196. Zettl A, Ott G, Makulik A et al. Chromosomal gains at 9q characterize enteropathy-Type T cell lymphoma. Am. J. Pathol. 161(5), 1635-1645 (2002
197. Wlodarska I, Martin-Garcia N, Achten R et al. Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T cell lymphoma: Isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. Genes Chromosomes Cancer 33(3), 243-251 (2002
198. Almire C, Bertrand P, Ruminy P et al. PVRL2 is translocated to the TRA@ locus in t(14;19) (q11;q13)-positive peripheral T cell lymphomas. Genes Chromosomes Cancer 46(11), 1011-1018 (2007
199. Lepretre S, Buchonnet G, Stamatoullas A et al. Chromosome abnormalities in peripheral T cell lymphoma. Cancer Genet. Cytogenet. 117(1), 71-79 (2000
200. Morris SW, Kirstein MN, Valentine MB et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263(5151), 1281-1284 (1994
201. Batista DA, Vonderheid EC, Hawkins A et al. Multicolor fluorescence in situ hybridization (SKY) in mycosis fungoides and Sezary syndrome: Search for recurrent chromosome abnormalities. Genes Chromosomes Cancer 45(4), 383-391 (2006